Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165697 | 0.86 | CYP1A2 (0.57) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL1908800 | 0.85 | CYP1A2 (0.55) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL1428085 | 0.84 | CYP1A2 (0.48) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL6329652 | 0.83 | GAA (0.52) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL15183506 | 0.83 | CYP1A2 (0.53) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL12561116 | 0.83 | GAA (0.54) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL10250453 | 0.83 | CYP1A2 (0.53) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL12933282 | 0.83 | CYP1A2 (0.53) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL15183507 | 0.83 | CYP1A2 (0.53) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL15183505 | 0.83 | CYP1A2 (0.53) | ALDH1A1TRPA1GAAMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110662746-B | Compounds as orally administered prodrugs of beta-lactamase inhibitors, pharmaceutical compositions thereof and use for treating bacterial infections | 阿里萨制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-12269832-B2 | Lithium borate compound, additive for lithium secondary battery, non-aqueous electrolyte solution for lithium secondary battery, lithium secondary battery precursor, and lithium secondary battery and method of producing the same | MITSUI CHEMICALS, INC. (JP) | 2025-04-08 | — | — | US | disclosed |
| EP-3828188-B1 | LITHIUM BORATE COMPOUND, ADDITIVE FOR LITHIUM SECONDARY CELL, NONAQUEOUS LIQUID ELECTROLYTE FOR LITHIUM SECONDARY CELL, LITHIUM SECONDARY CELL PRECURSOR, AND LITHIUM SECONDARY CELL AND METHOD FOR MANUFACTURING SAME | MITSUI CHEMICALS INC (JP) | 2024-11-13 | — | — | EP | disclosed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-117417355-A | Fused heterocyclic compound, preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-7326719-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| WO-2007125364-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1606258-A1 | CATHEPSIN S INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050222145-A1 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2004083182-A1 | CATHEPSIN S INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040180886-A1 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4709/4885TRPA1 4840/4885GAA 1678/4885 |
| US-20040180886-A1 | Cathepsin S inhibitors | CTSS, CTSB, CTSZ | ALDH1A1 2916/4885TRPA1 2526/4885GAA 49/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | ALDH1A1 4610/4885TRPA1 4691/4885GAA 1283/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | ALDH1A1 4861/4885TRPA1 4574/4885GAA 4203/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | ALDH1A1 1079/4885TRPA1 3806/4885GAA 4203/4885 |
| US-12269832-B2 | Lithium borate compound, additive for lithium secondary battery, non-aqueous electrolyte solution for lithium secondary battery, lithium secondary battery precursor, and lithium secondary battery and method of producing the same | SLC9B2, LDHB, SLC26A3 | ALDH1A1 1671/4885TRPA1 980/4885GAA 733/4885 |
| US-20050222145-A1 | Cathepsin S inhibitors | CTSS, CTSB, CTSZ | ALDH1A1 3363/4885TRPA1 2516/4885GAA 47/4885 |
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | ALDH1A1 775/4885TRPA1 405/4885GAA 642/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | ALDH1A1 3842/4885TRPA1 2245/4885GAA 894/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | ALDH1A1 2528/4885TRPA1 1955/4885GAA 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.